Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Welcome To The Workplace With A Difference
Our vision is to fearlessly lead the way to create a world with better brain health – a vision we can only achieve with the help of our amazing team of highly knowledgeable, deeply passionate individuals.
At Sage, we believe that life is more than just a destination. We’re concerned with the journey, and we care deeply about everyone contributing to and benefiting from our own company journey. This means helping people discover the right path for them and carefully guiding colleagues along the way.
Stock Symbol:
SAGE
Fly-through video of our Cambridge Office. Feel what it's like to be on site.
404 articles about Sage Therapeutics
-
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
4/17/2024
Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with mild cognitive impairment in Parkinson’s Disease.
-
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases.
-
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
4/11/2024
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Thursday, April 25, 2024 at 8:00 a.m. ET to review first quarter 2024 financial results and discuss recent business updates.
-
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
-
Sage Therapeutics to Present at Upcoming March Investor Conferences
2/28/2024
Sage Therapeutics, Inc. announced today that the Company will present at the following upcoming investor conferences in March.
-
Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
2/14/2024
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
-
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
1/31/2024
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, February 14, 2024 at 8:00 a.m. ET to review fourth quarter and full year 2023 financial results and discuss recent business updates.
-
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
1/8/2024
Sage Therapeutics, Inc. announced that Chief Executive Officer Barry Greene will discuss the Company’s key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
-
Sage Therapeutics Announces Changes to Board of Directors - Jan 08, 2024
1/8/2024
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the retirement of Kevin Starr from the company’s board of directors.
-
With recent scientific advances, milestone approvals and increased dealmaking, the future of treatment for neurological diseases looks brighter—but continued investment, collaboration and patient-focused efforts are key.
-
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
1/2/2024
Sage Therapeutics, Inc. announced today that the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.
-
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
12/14/2023
Biogen Inc. and Sage Therapeutics, Inc. announced ZURZUVAE™ 50 mg CIV is now available by prescription for the treatment of postpartum depression for adults in the United States, with product already at specialty pharmacies and delivered to patients.
-
Sage Therapeutics to Present at Upcoming November 2023 Investor Conferences
11/8/2023
Sage Therapeutics, Inc. announced that the Company will present at the following upcoming investor conferences in November.
-
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
11/7/2023
Sage Therapeutics, Inc. reported business highlights and financial results for the third quarter ended September 30, 2023.
-
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
10/24/2023
Sage Therapeutics, Inc. announced that it will host a live webcast on Tuesday, November 7, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and discuss recent business updates.
-
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
10/18/2023
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced the U.S. Food and Drug Administration granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease.
-
Week in Review: Amgen-Horizon Deal Moves Forward, First 10 Drugs for IRA Price Negotiation, Layof...
9/1/2023
$27.8B Amgen-Horizon deal gets FTC clearance with restrictions; the White House names first 10 drugs subject to Medicare price negotiations; Sage Therapeutics axes 40% of staff. -
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
8/31/2023
Sage Therapeutics, Inc., announced plans to reorganize its business operations and pipeline priorities to support goals for long-term business growth, including the planned commercial launch of ZURZUVAE for women with postpartum depression in late 2023.
-
Following the FDA’s recent rejection of zuranolone in major depressive disorder, Sage Therapeutics has launched a strategic reorganization initiative including a 40% reduction in headcount.